{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Skin+to+Skin&page=12",
    "query": {
      "condition": "Skin to Skin",
      "page": 12
    },
    "page_size": 10
  },
  "pagination": {
    "page": 12,
    "page_size": 10,
    "total_count": 6433,
    "total_pages": 644,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Skin+to+Skin&page=13&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Skin+to+Skin&page=11&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-22T10:38:24.978Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05457842",
      "title": "A Study to Find the Best Dose of ASP5354 to Show Lymph Nodes in People With Breast Cancer or Melanoma During Surgery",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Sentinel Lymph Node Biopsy",
        "Breast Cancer",
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "pudexacianinium chloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2022-08-10",
      "completion_date": "2022-09-20",
      "has_results": true,
      "last_update_posted_date": "2024-11-20",
      "last_synced_at": "2026-10-22T10:38:24.978Z",
      "location_count": 1,
      "location_summary": "Orange, California",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05457842"
    },
    {
      "nct_id": "NCT02213042",
      "title": "Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neoplasms, Breast"
      ],
      "interventions": [
        {
          "name": "Lapatinib",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Aromatase Inhibitors (AIs)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 42,
      "start_date": "2014-10-24",
      "completion_date": "2020-06-04",
      "has_results": true,
      "last_update_posted_date": "2021-10-13",
      "last_synced_at": "2026-10-22T10:38:24.978Z",
      "location_count": 3,
      "location_summary": "Mobile, Alabama • Boston, Massachusetts • Houston, Texas",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02213042"
    },
    {
      "nct_id": "NCT00646958",
      "title": "Safety and Efficacy Study of Oxazolidinones to Treat Uncomplicated Skin Infections",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Infectious Skin Diseases",
        "Bacterial Skin Diseases",
        "Staphylococcal Skin Infections",
        "Streptococcal Infections",
        "Abscess"
      ],
      "interventions": [
        {
          "name": "Radezolid",
          "type": "DRUG"
        },
        {
          "name": "Linezolid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Melinta Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 150,
      "start_date": "2007-12",
      "completion_date": "2008-04",
      "has_results": true,
      "last_update_posted_date": "2014-03-27",
      "last_synced_at": "2026-10-22T10:38:24.978Z",
      "location_count": 19,
      "location_summary": "Montgomery, Alabama • Long Beach, California • Los Angeles, California + 16 more",
      "locations": [
        {
          "city": "Montgomery",
          "state": "Alabama"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "California"
        },
        {
          "city": "Sylmar",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00646958"
    },
    {
      "nct_id": "NCT05516758",
      "title": "A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid Arthritis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Rheumatoid Arthritis",
        "Arthritis",
        "Joint Diseases",
        "Musculoskeletal Diseases",
        "Rheumatic Diseases",
        "Connective Tissue Diseases",
        "Autoimmune Diseases",
        "Immune System Diseases"
      ],
      "interventions": [
        {
          "name": "Peresolimab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 491,
      "start_date": "2022-08-31",
      "completion_date": "2025-01-17",
      "has_results": true,
      "last_update_posted_date": "2025-12-04",
      "last_synced_at": "2026-10-22T10:38:24.978Z",
      "location_count": 54,
      "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Glendale, Arizona + 43 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05516758"
    },
    {
      "nct_id": "NCT07734415",
      "title": "Long-term Safety and Efficacy Evaluation of IMG-007 in Participants With Moderate-to-Severe Atopic Dermatitis",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Atopic Dermatitis",
        "Atopic Dermatitis Eczema",
        "Eczema"
      ],
      "interventions": [
        {
          "name": "IMG-007",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Inmagene LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 400,
      "start_date": "2026-06-05",
      "completion_date": "2028-03",
      "has_results": false,
      "last_update_posted_date": "2026-07-29",
      "last_synced_at": "2026-10-22T10:38:24.978Z",
      "location_count": 16,
      "location_summary": "Lancaster, California • Los Angeles, California • Ocala, Florida + 13 more",
      "locations": [
        {
          "city": "Lancaster",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Ocala",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Rolling Meadows",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07734415"
    },
    {
      "nct_id": "NCT01097135",
      "title": "Evaluating the Effectiveness of 2 Surgical Skin Preparation Methods in Reducing Surgical Wound Drainage After Total Hip or Knee Replacement",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Drainage"
      ],
      "interventions": [
        {
          "name": "Duraprep Surgical Solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rothman Institute Orthopaedics",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 600,
      "start_date": "2010-03",
      "completion_date": "2012-12",
      "has_results": false,
      "last_update_posted_date": "2013-09-17",
      "last_synced_at": "2026-10-22T10:38:24.978Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01097135"
    },
    {
      "nct_id": "NCT01397708",
      "title": "Safety Study of Adenovirus Vector Engineered to Express hIL-12 in Combination With Activator Ligand to Treat Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "INXN-2001",
          "type": "BIOLOGICAL"
        },
        {
          "name": "INXN-1001",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Alaunos Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2011-08",
      "completion_date": "2014-09",
      "has_results": true,
      "last_update_posted_date": "2025-10-29",
      "last_synced_at": "2026-10-22T10:38:24.978Z",
      "location_count": 9,
      "location_summary": "Los Angeles, California • Park Ridge, Illinois • Goshen, Indiana + 6 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Park Ridge",
          "state": "Illinois"
        },
        {
          "city": "Goshen",
          "state": "Indiana"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01397708"
    },
    {
      "nct_id": "NCT00023790",
      "title": "Photodynamic Therapy in Treating Patients With Skin Cancer or Solid Tumors Metastatic to the Skin",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer",
        "Head and Neck Cancer",
        "Lymphoma",
        "Metastatic Cancer",
        "Non-melanomatous Skin Cancer",
        "Sarcoma"
      ],
      "interventions": [
        {
          "name": "silicon phthalocyanine 4",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Case Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2001-08",
      "completion_date": "2006-02",
      "has_results": false,
      "last_update_posted_date": "2011-08-24",
      "last_synced_at": "2026-10-22T10:38:24.978Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00023790"
    },
    {
      "nct_id": "NCT01979016",
      "title": "Study to Determine the Safety and Effectiveness of Dupilumab for Treatment of Atopic Dermatitis (AD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Atopic Dermatitis (AD)"
      ],
      "interventions": [
        {
          "name": "Dupilumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Background treatment",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 54,
      "start_date": "2013-12-31",
      "completion_date": "2015-01-31",
      "has_results": true,
      "last_update_posted_date": "2020-03-18",
      "last_synced_at": "2026-10-22T10:38:24.978Z",
      "location_count": 3,
      "location_summary": "Chicago, Illinois • New York, New York • Dallas, Texas",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01979016"
    },
    {
      "nct_id": "NCT03654755",
      "title": "Study to Evaluate Long-Term Safety of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Atopic Dermatitis"
      ],
      "interventions": [
        {
          "name": "ASN002",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Asana BioSciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 162,
      "start_date": "2018-09-29",
      "completion_date": "2019-10-29",
      "has_results": true,
      "last_update_posted_date": "2023-09-18",
      "last_synced_at": "2026-10-22T10:38:24.978Z",
      "location_count": 31,
      "location_summary": "Anniston, Alabama • Birmingham, Alabama • Fremont, California + 25 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fremont",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03654755"
    }
  ]
}